Nanion Corporate Blog

 

19.09.2018: Joint Marketing and Sales Promotion with Ncardia

Nanion Technologies and Ncardia Sign Co-Marketing and Support Agreement to enhance Options for Cardiac Researchers


Munich, Germany and Cologne, Germany, September 19, 2018;
Nanion Technologies GmbH, a leading provider of instrumentation for ion channel drug discovery and screening, and the Ncardia Group, a leading developer, manufacturer, and service provider of human induced pluripotent stem cells (iPSCs) for safety and efficacy testing announced today that they have entered into a joint marketing and sales promotion agreement.

Click here to read the full press release.

Back to Overview

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok